Results 11 to 20 of about 224,020 (260)

Liver-Targeting of Interferon-Alpha with Tissue-Specific Domain Antibodies [PDF]

, 2013
PMCID: PMC3581439This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Trahtenherts, A Walker, Adam Walker, AM Wu, Armin Sepp, B Saunier, C. Andrew Boswell, CL Van Broekhoven, Clare Mudd, DJ Peng, DY Yang, E Dieperink, Edward Coulstock, ES Ward, F Pacifico, G Dusheiko, Gráinne Dunlevy, Jane Sosabowski, Jerome Burnet, JH Park, Julie Foster, KA Deal, Laura Goodall, LC Platanias, LJ Holt, LJ Holt, M Abe, M Loignon, M Spiess, Marie Davies, Milan Ovečka, MW Fried, MW Fried, P Kallinteri, R Duncan, R Gay, R Iorio, Rob Prince, T Eto, U Iyer, U Treichel, WM Pardridge, XQ Zhang, Y Zhang, YI Jeong, YY Seow   +45 more
core   +8 more sources

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]

, 2000
Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.
Berg, Thomas, Hoffmann, Robert M., Hopf, Uwe, Lafrenz, Michael, Leifeld, Ludger, Pape, Gerd R., Spengler, Ulrich, Teuber, Gerlinde, Zeuzem, Stefan   +8 more
core   +1 more source

Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. [PDF]

, 2003
Roughly 50% of patients with chronic hepatitis C, who relapsed after a previous monotherapy with interferon alpha, will respond in a sustained fashion to 24 weeks of re-therapy with the combination of interferon alpha plus ribavirin.
August-Jörg, B.S., Borovicka, J., Dufour, J.F., Gonvers, J.J., Henz, S., Hermann, R., Meyenberger, C., Renner, E.L., Weitz, M.   +8 more
core   +1 more source

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources

Porcine innate and adaptative immune responses to influenza and coronavirus infections [PDF]

, 2006
Both innate and adaptative immune responses contribute to the control of infectious diseases, including by limiting the spreading of zoonotic diseases from animal reservoirs to humans.
Asselin-Paturel, Baudoux, BERNARD CHARLEY, Brim, Charley, Charley, Charley, Chen, Chinsangaram, Corthier, Fitzgerald-Bocarsly, Guzylack-Piriou, Heinen, KRISTIEN VAN REETH, La Bonnardière, Laude, Laude, Le Bon, Lim, Liu, Palese, Peiris, Pestka, Riffault, Riffault, Riffault, Rothenfusser, SABINE RIFFAULT, Saif, Siegal, Summerfield, Tu, Tudor, Van Reeth, Van Reeth, van Reeth   +35 more
core   +2 more sources

Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera. [PDF]

, 2012
We describe the course and likely pathophysiology of impending anterior ischemic optic neuropathy (AION) and retinal vein occlusion in a 56-year-old man with polycythemia vera managed with interferon alpha for 2 years.
Hirsch, Louis K, Rue, Kelly S, Sadun, Alfredo A   +2 more
core   +1 more source

Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis [PDF]

, 2000
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.
Amann, B., Grunze, Heinz, Loeschke, K., Schlösser, S., Schmidt, F., Schäfer, Martin   +5 more
core   +1 more source

Pro-inflammatory signaling by IL-10 and IL-22: bad habit stirred up by interferons? [PDF]

, 2013
Interleukin (IL)-10 and IL-22 are key members of the IL-10 cytokine family that share characteristic properties such as defined structural features, usage of IL-10R2 as one receptor chain, and activation of signal transducer and activator of ...
Mühl, Heiko
core   +2 more sources

The treatment of hepatitis C: history, presence and future [PDF]

, 2004
The treatment of chronic hepatitis C has made remarkable progress over the past two decades. For interferon-alpha monotherapy, sustained virological response rates were between 2 and 9% in genotype 1 and between 16 and 23% in genotypes ...
Knegt, R.J. (Robert) de, Orlent, H. (Hans), Schalm, S.W. (Solko), Veldt, B.J. (Bart), Vrolijk, J.M. (Jan)   +4 more
core   +6 more sources

The sustained virologic response of nonresponder hepatitis C virus patients with retreatment

Indian Journal of Pathology and Microbiology, 2011
Background: Pegylated interferon and ribavirin combination therapy remain the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the large number of studies in treatment-naive patients, the effectiveness of retreatment in ...
Sila Cetin Akhan, Erdem Gurel, Murat Sayan   +2 more
doaj   +1 more source